These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 18935928)

  • 21. A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance).
    Halfdanarson TR; Foster NR; Kim GP; Meyers JP; Smyrk TC; McCullough AE; Ames MM; Jaffe JP; Alberts SR
    Oncologist; 2019 May; 24(5):589-e160. PubMed ID: 30679315
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Tolerability of Second-line Nab-paclitaxel and Gemcitabine After Failure of First-line FOLFIRINOX for Advanced Pancreas Cancer: A Single-institution Experience.
    Zhang H; Kellett C; Lambert P; Kim CA
    Clin Colorectal Cancer; 2018 Sep; 17(3):e451-e456. PubMed ID: 29631907
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database.
    Shin S; Park CM; Kwon H; Lee KH
    BMC Cancer; 2016 Jul; 16():443. PubMed ID: 27400734
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer.
    Altwegg R; Ychou M; Guillaumon V; Thezenas S; Senesse P; Flori N; Mazard T; Caillo L; Faure S; Samalin E; Assenat E
    World J Gastroenterol; 2012 Mar; 18(12):1357-64. PubMed ID: 22493549
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who have progressed on gemcitabine-based therapy.
    Lee MG; Lee SH; Lee SJ; Lee YS; Hwang JH; Ryu JK; Kim YT; Kim DU; Woo SM
    Chemotherapy; 2013; 59(4):273-9. PubMed ID: 24457620
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Association of Drug-Funding Reimbursement With Survival Outcomes and Use of New Systemic Therapies Among Patients With Advanced Pancreatic Cancer.
    Raphael MJ; Raskin W; Habbous S; Tai X; Beca J; Dai WF; Arias J; Forbes L; Gavura S; Biagi JJ; Earle CC; Chan KKW
    JAMA Netw Open; 2021 Nov; 4(11):e2133388. PubMed ID: 34779846
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Options for the treatment of gemcitabine-resistant advanced pancreatic cancer.
    Gounaris I; Zaki K; Corrie P
    JOP; 2010 Mar; 11(2):113-23. PubMed ID: 20208317
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemotherapy in Pancreatic Cancer: A Systematic Review.
    Hajatdoost L; Sedaghat K; Walker EJ; Thomas J; Kosari S
    Medicina (Kaunas); 2018 Jul; 54(3):. PubMed ID: 30344279
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Systematic Review and Network Meta-analysis.
    Takumoto Y; Sasahara Y; Narimatsu H; Akazawa M
    JAMA Netw Open; 2022 Jan; 5(1):e2145515. PubMed ID: 35099549
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metastatic pancreatic cancer: Is there a light at the end of the tunnel?
    Vaccaro V; Sperduti I; Vari S; Bria E; Melisi D; Garufi C; Nuzzo C; Scarpa A; Tortora G; Cognetti F; Reni M; Milella M
    World J Gastroenterol; 2015 Apr; 21(16):4788-801. PubMed ID: 25944992
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
    Ettrich TJ; Berger AW; Perkhofer L; Daum S; König A; Dickhut A; Wittel U; Wille K; Geissler M; Algül H; Gallmeier E; Atzpodien J; Kornmann M; Muche R; Prasnikar N; Tannapfel A; Reinacher-Schick A; Uhl W; Seufferlein T
    BMC Cancer; 2018 Dec; 18(1):1298. PubMed ID: 30594153
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pancreatic Cancer Survival Increases with Chemo Combo.
    Cancer Discov; 2016 Aug; 6(8):OF3. PubMed ID: 27363975
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
    Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
    BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of metastatic pancreatic adenocarcinoma: a review.
    Thota R; Pauff JM; Berlin JD
    Oncology (Williston Park); 2014 Jan; 28(1):70-4. PubMed ID: 24683721
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MM-398 achieves primary endpoint of overall survival in phase III study in patients with gemcitabine refractory metastatic pancreatic cancer.
    Saif MW
    JOP; 2014 May; 15(3):278-9. PubMed ID: 24865544
    [No Abstract]   [Full Text] [Related]  

  • 36. Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA).
    Hecht JR; Lonardi S; Bendell J; Sim HW; Macarulla T; Lopez CD; Van Cutsem E; Muñoz Martin AJ; Park JO; Greil R; Wang H; Hozak RR; Gueorguieva I; Lin Y; Rao S; Ryoo BY
    J Clin Oncol; 2021 Apr; 39(10):1108-1118. PubMed ID: 33555926
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment landscape of metastatic pancreatic cancer.
    De Dosso S; Siebenhüner AR; Winder T; Meisel A; Fritsch R; Astaras C; Szturz P; Borner M
    Cancer Treat Rev; 2021 May; 96():102180. PubMed ID: 33812339
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Second-line treatment for pancreatic cancer.
    Kaddis N; Saif MW
    JOP; 2014 Jul; 15(4):344-7. PubMed ID: 25076339
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical outcomes of FOLFIRINOX and gemcitabine-nab paclitaxel for metastatic pancreatic cancer in the real world setting.
    Franco F; Camara JC; Martín-Valadés JI; López-Alfonso A; Marrupe D; Gutiérrez-Abad D; Martínez-Amores B; León A; Juez I; Pérez M; Royuela A; Ruiz-Casado A
    Clin Transl Oncol; 2021 Apr; 23(4):812-819. PubMed ID: 32857340
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is there a standard of care for the management of advanced pancreatic cancer?. Highlights from the Gastrointestinal Cancers Symposium. Orlando, FL, USA. January 25-27, 2008.
    Saif MW
    JOP; 2008 Mar; 9(2):91-8. PubMed ID: 18326919
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.